✉ info@591daili.com☎ +86-18553102138
📞 WhatsApp中文
591daili 济南圣和化工
Home › Product Catalog › Bosutinib

Bosutinib

CAS 380843-75-4C26H29Cl2N5O3MW 530.4

Bosutinib (CAS No. 380843-75-4) is supplied by Jinan Shenghe Chemical Co., Ltd. with a typical purity of 按批次COA提供(不公开发布). Main applications include Pharmaceutical Intermediates & APIs. Bulk quantities are available with COA; purity and packaging are subject to batch COA and order confirmation.

Specifications

CAS Number380843-75-4
Molecular FormulaC26H29Cl2N5O3
Molecular Weight530.4
Melting Point131
LogP3.34
Purity按批次COA提供(不公开发布)
Packaging按订单/批次确认(不公开发布)
ApplicationsPharmaceutical Intermediates & APIs
CategoryPharmaceutical Intermediates & APIs

Where it is used

Pharmaceutical Intermediates & APIs

Packaging & Supply

Packaging按订单/批次确认(不公开发布)
Purity按批次COA提供(不公开发布)
StorageSealed, cool and dry place
Lead TimeIn stock / per order

Documents & Support

COA provided with every batch; MSDS and technical documents available on request. Email us with product name and CAS number for a quote within one business day.

Frequently Asked Questions

What is the CAS number of Bosutinib?

The CAS number of Bosutinib is 380843-75-4.

What purity and packaging are available?

Typical purity is 按批次COA提供(不公开发布), supplied in 按订单/批次确认(不公开发布), with COA provided.

What are the applications of Bosutinib?

Main applications include Pharmaceutical Intermediates & APIs.

How do I buy Bosutinib or get a quote?

Email info@591daili.com or reach us on WhatsApp with the product name, CAS number and required quantity; quotes within one business day. Supplier: Jinan Shenghe Chemical Co., Ltd..

PubChem Public Data

Description

Bosutinib · CAS 380843-75-4 · C26H29Cl2N5O3. UNII 5018V4AEZ0. Melting Point: 131; LogP: 3.34.

Identification

CAS Registry Number380843-75-4
PubChem CID5328940
Molecular formulaC26H29Cl2N5O3
IUPAC name4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
UNII (FDA)5018V4AEZ0

Computed Descriptors

Molecular Weight530.4
XLogP35.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count9
Exact Mass529.1647452
Monoisotopic Mass529.1647452
Topological Polar Surface Area82.9
Heavy Atom Count36
Formal Charge0

Physical & Chemical Properties

Melting Point131
LogP3.34

Physical description & handling notes

  • A greater likelihood of response and a greater likelihood of safety events were observed with higher bosutinib exposure in clinical studies. The time course of bosutinib pharmacodynamic response has not been fully characterized. At a single oral dose of 500 mg bosutinib with ketoconazole (a strong CYP3A inhibitor), bosutinib does not prolong the QT interval to any clinically relevant extent.

GHS Hazard Classification

Reported hazard statementsH317 (41.7%), H319 (59.7%), H413 (55.6%)

H317 (41.7%): May cause an allergic skin reaction [Warning Sensitization, Skin]

H319 (59.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

Documented Uses

  • Bosutinib is indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy. It is also indicated for the treatment of adult patients with accelerated or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy.
  • Bosutinib is a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury.
  • Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors
  • Bosutinib is approved to treat:
  • • Chronic myelogenous leukemia (CML) that is Philadelphia chromosomepositive. It is used:
  • • In adults and children aged 1 year and older with chronic phase CML that is newly diagnosed or cannot be treated with or did not respond to other treatment.

Synonyms

Bosutinib; 380843-75-4; SKI-606; SKI 606; 5018V4AEZ0; SK-606; CHEBI:39112; DTXSID10861568; bosutinibum; uglysycpd2; RefChem:58901; DTXCID40207910; L01XE14; 4-Anilinobenzo(g)quinoline-3-carbonitrile; 700-455-1; 943-866-3

Frequently Asked Questions

What are the CAS number and molecular formula of Bosutinib?

CAS 380843-75-4; molecular formula C26H29Cl2N5O3; molecular weight — g/mol.

What other names is Bosutinib known by?

Bosutinib, 380843-75-4, SKI-606, SKI 606, 5018V4AEZ0, SK-606.

Is Bosutinib classified as hazardous?

Hazard statements reported: H317, H319, H413.

What are the key physical properties of Bosutinib?

Melting Point: 131; LogP: 3.34.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.

You may also need

acycloguanosineCAS 59277-89-3›
AtenololCAS 29122-68-7›
AcetamideCAS 60-35-5›
AdenineCAS 73-24-5›
AmpicillinCAS 69-53-4›
AzithromycinCAS 83905-01-5›
Amoxicillin trihydrateCAS 61336-70-7›
Atorvastatin CalciumCAS 134523-03-8›

Get a quote for Bosutinib

Supplier: Jinan Shenghe Chemical Co., Ltd. · Reply within one business day.

Email Inquiry WhatsApp
鲁ICP备19031700号-1